NEW YORK, NY Set before the 2016 presidential elections,Dreams on Fire, a groundbreaking play by Professor Jan Balakian and directed by Nora Armani, explores college students, mental health and the transmission of trauma in history across generations via the Armenian Genocide.

The play traces back the causes of Aram Sarkissians anxiety and mental health issues to intergenerational trauma through epigenetics. While the subject is dark, the characters are full of life and humor. The story takes place in Fort Lee, NJ and in retrospect prophetically refers to the four years of disastrous leadership that await the US. Arams grandmother Hripsime recounts the experiences of her own mother, surviving the Genocide as a young woman, and how she ends up in the US.

The riveting tale links the past to the present and explains mental health today as it is traced back to past trauma, even if such trauma has not touched the victim directly. Never before has there been a play that explores college students, mental health and the Armenian Genocide within the context of the 2016 election.

The cast of the Zoom reading includes Constance Cooper,Sam Arthur,Emma Giorgio andDalita Getzoyan. Donna Heffernan is assistant director. The reading, which is open to the public, will take place onWednesday, April 27, at 5:00 PM EDT presented as part of the Kean University Research Day activities. A Q&A session with Balakian, faculty members and attendees will follow the reading. FREE and open to the public.

The Armenian Genocide perpetrated by Ottoman Turkey on the Armenians is a fact widely substantiated by historians, archivists and eyewitnesses whose accounts have been recorded and preserved. And yet, the countries who have officially recognized it are few, mainly to appease Turkey.

US presidents, under pressure from Turkey, have played word gymnastics calling the events by several different names, shying away from its correct name of Genocide. President Joe Biden acknowledged the Armenian Genocide in 2021, and this year, on the 107th anniversary of the commemoration, confirmed that the events that started on April 24, 1915 and lasted until 1923, were in fact Genocide, causing the death of over 1.5 million Armenians and wiping out an entire population from its ancestral lands.

Guest contributions to the Armenian Weekly are informative articles or press releases written and submitted by members of the community.

Read the original here:
Dreams on Fire sheds light on epigenetics, collective trauma of genocide traveling through generations - Armenian Weekly

SIRIUS MANAGEMENT CONSULTING

The global biomarkers market was valued at $45 billion in 2021 and is expected to reach $86 billion by 2027.

Chicago, April 27, 2022 (GLOBE NEWSWIRE) -- According to the latest research report by Arizton, the biomarkers market will grow at a CAGR of over 11% during 2022-2027. Digital biomarkers have become an exciting new tool for advancing precision medicine and supporting clinical trials. They are collected using digital devices that are portable, wearable, implantable, or digestible. Digital biomarkers can be objective, quantifiable, physiological, and behavioral measures. Digital biomarkers have majorly impacted the neurology field. In neurology, several digital biomarkers are being tested for feasibility and reliability in Parkinsons and Alzheimer's disease and clinical outcome assessments.

With the emergence of innovative technologies, the identification and validation of a biomarker are becoming key elements of personalized medicine. For example, in cancer, personalized medicine uses specific biomarker information that has been measured from a persons tumor to help plan treatment regimes, monitor a treatments response, or aid in determining a prognosis.

BIOMARKERS MARKET REPORT SCOPE

REPORT ATTRIBUTE

DETAILS

MARKET SIZE (2027)

$86 Billion

CAGR (2022-2027)

Over 11%

BASE YEAR

2021

FORECAST YEAR

2022-2027

LARGEST MARKET

North America

FASTEST MARKET

Europe

MARKET SEGMENTATION

Indication, Application, Type, and Geography

REGION

North America, Europe, APAC, Latin America, and Middle East & Africa

COUNTRIES COVERED

US, Canada, Germany, France, UK, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, Argentina, Turkey, South Africa, and Saudi Arabia

KEY VENDORS

Abbott, bioMrieux, Biohit Oyj, Centogene, Creative Diagnostics, F. Hoffmann-La Roche, Fujirebio, GE Healthcare, TAmiRNA

Click Here to Download the Free Sample Report

The biomarker approach in developing personalized medicine helps in clinical decisions, personalized therapies, and improved research and development (R&D) models. Developing and providing access to novel personalized medicine products and services are only part of what is needed to achieve better human health by tailoring treatment based on the presence or absence of specific biomarkers.

Story continues

Increased Discovery of Epigenetic Biomarkers in Oncology

Epigenetics, genomic, and epigenomic technologies have opened new and promising landscapes for healthcare professionals, enabling them to diagnose and monitor diseases more precisely, effectively, and rapidly. It is obvious that epigenetics is revolutionizing the potential of biomedicine and clinical diagnostics, therefore, contributing to the future development of precision medicine.

Key Offerings:

Market Size & Forecast by Volume | 20212028

Market Dynamics Leading trends, growth drivers, restraints, and investment opportunities

Market Segmentation A detailed analysis by indication, application, type, and geography

Competitive Landscape 9 key vendors and 22 other vendors

To know more! https://www.arizton.com/market-reports/biomarkers-market

Key Insights

Biomarkers in the field of oncology have revolutionized diagnostics and treatment pathways. Oncology indications constitute of largest share because biomarkers are being largely used for cancer research and diagnostics due to their high prevalence worldwide.

Diagnostics dominated the application segment. However, the application of biomarkers in drug discovery & development is expected to grow significantly during the forecast period because biomarkers studies are expected to become an integral part of the drug development process with the aim of developing more effective drugs at a lower cost

North America is the largest market for biomarkers. The increase in R&D expenditures and funding for biomarker-driven drug discovery & development and precision medicine is one of the major driving factors.

APAC is anticipated to exhibit the highest CAGR of 13.96% during the forecast period. Increasing developments and incorporation of advanced technologies to enhance biomarker-based testing and increasing demand for biomarkers in drug development is driving the demand in APAC.

The COVID-19 pandemic had a negative impact on the market. Several biomarkers research activities got postponed as most of the research activities were focused on COVID-19 indications.

Market Segmentation

Indication

Oncology

Cardiology

Neurology

Immunology

Others

Application

Type

Diagnostic Biomarker

Monitoring Biomarker

Prognostic Biomarker

Predictive Biomarker

Susceptibility Biomarker

Other Biomarker

Region

North America

Europe

Germany

France

UK

Italy

Spain

APAC

Japan

China

India

South Korea

Australia

Latin America

Middle East & Africa

Turkey

South Africa

Saudi Arabia

Competition Overview

The biomarkers market is highly dynamic, with the presence of several global, regional, and local players engaged in biomarkers discovery and development in collaboration with several research organizations. The growth of the biomarkers market majorly depends on advancements in technology and investments in R&D to discover and develop more biomarkers. Global players are focusing on developing more biomarkers and expanding their product portfolio to remain competitive in the market. The key players are also engaged in strategic acquisitions as part of their inorganic growth strategy to remain competitive and grow in the market. Through mergers & acquisitions, major players continue to expand their market shares. Furthermore, they are also growing through partnerships and collaborations with several research organizations to develop biomarkers for new testing strategies.

Explore our healthcare lifesciences profile to know more about the industry.

Click Here to Download the Free Sample Report

Read some of the top-selling reports:

About Arizton:

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.

Click Here to Contact Us

Call: +1-312-235-2040+1 302 469 0707

See the rest here:
Digital biomarkers - An Emerging tool in precision Medicines. The Biomarkers Market to Reach $86 Billion by 2027 - Arizton - Yahoo Finance

NEW ULM May is Mental Health Awareness Month, and this year the need for mental health education and services has never been higher.

Mental Health Month started in 1949 to increase awareness of the importance of mental health and wellness in Americans lives and to celebrate recovery from mental illness.

After more than two years of societal disruption from the COVID-19 pandemic, this year several Brown County organizations are working to promote the month.

Mental Health Awareness month is represented by a green ribbon. Throughout the month green ribbons will be displayed at the Community Service Building, 1117 Center St. and Brown County drop-in Center, 1113 Center St.

From 9 a.m. to 2:30 p.m. Tuesday, May 3, The Heart of New Ulm Brown County Mental Health and Wellbeing Action Team, in collaboration with the Families First Collaborative of Brown County, will be offering a presentation called Understanding NEAR Science: Building Self-Healing Communities.

The presentation covers the basics of NEAR science which stands for neurobiology, epigenetics, Adverse Childhood Experience (ACE) and resilience a study of the relationship between health risks and behaviors to exposure to adverse childhood experiences. People who experienced abuse, neglect or household dysfunction as a child were more likely to have increased risks of chronic health conditions and death, as well as increased participation in risky behaviors.

Additional research has shown experiences like racism, neighborhood safety, community violence, bullying, and living in foster care can increase the likelihood of increased health risks.

Over the last few decades, research has expanded on what can be done to prevent adverse childhood experiences and how people can move past their experiences to live healthy and safe lives.

The building self-healing communities presentation is intended to start an ongoing communitywide conversation between professionals, law enforcement, parents, faith leaders, educators and neighbors about how to change the narrative of the future of communities.

The Understanding NEAR Science: Building Self-Healing Communities presentation is free and open to the public; however, space is limited, and registration is required. For information and to register, visit https://tinyurl.com/NEARscience.

Similar presentation have been held in Brown County before, but due to the COVID pandemic few public health presentation were possible. The pandemic also created a need for greater need for mental health services as many were impacted by the health crisis.

The Brown County Local Advisory Committee will be hosting a Mental Health Walk Tuesday, May 17, Harman Park in New Ulm. The walk is open to everyone wishing to show support for mental health in the community. Registration for the walk is at 12:30 p.m. at Harman Park. There will be two routes to accommodate differing physical capabilities. The walk will be followed by professional speakers sharing their knowledge and experience regarding mental health recovery.

The local advisory committee is made of members of the public, professionals and providers with an interest in mental health and support in the county. The goal of the committee is to have a conversation about mental health, advocacy, combatting stigma and creating a supportive community for those struggling with their mental health.

Today's breaking news and more in your inbox

Read more:
NEAR science: good for what ails stressed communities - NUjournal

Sprint Bioscience today announces that the NIMA program is focused on developing a precision medicine treatment that targets the protein Nicotinamide N-methyl transferase (NNMT). The program will be launched in connection with Sprint Bioscience participating in the pharmaceutical industry's largest annual partnering meeting, BIO International Convention, in San Diego, June 13-16, 2022.

The NNMT gene is overexpressed in multiple cancers and high levels of NNMT is linked to poor prognosis in several tumor types, including gastric cancer, ovarian cancer and glioblastoma. Glioblastoma, which is one of the most aggressive cancers, accounts for about 35 percent of all brain tumors and is thus one of the main challenges in today's cancer care. The median survival for patients with glioblastoma is approximately 1214 months. Gastric cancer is the fifth most common cancer globally and the median survival for metastatic gastric cancer is only 15-17 weeks. Consequently, there is a large remaining unmet medical need for improved treatment alternatives for these indications.We are very pleased with the progress of the NIMA program, which entails atruly promising opportunity to develop a novel cancer treatment alternative. Our fragment-based drug development platform has enabled us once more to rapidly develop highly potent inhibitors of a novel target. We are very much looking forward to introducing the NIMA program to potential partners", said Martin Andersson, Chief Scientific Officer at Sprint Bioscience.About the NNMT protein and cancerThe NNMT protein is upregulated in several cancers and is involved in various important processes in the survival of cancer cells at the interface between epigenetics, tumor metabolism and immunosuppression.

Upregulation of NNMT has been shown to promote tumor growth through epigenetic reprogramming of both cancer cells and stromal cell types in the tumor. Elevated NNMT have also been shown to affect cell metabolism, such as levels of S-adenosylmethionine (SAM) and biosynthesis of NADH. The product produced by NNMT, 1-methylnicotinamide (1MNA), is excreted by tumor cells and inactivates the function of immune cells in the tumor.

Studies have also shown that the ability of CAR-T cells to eliminate tumor cells is affected by 1MNA, which opens up for treatments where NNMT inhibitors can be used in combination with various types of immunotherapies, including cell therapies such as CAR-T.

Read more from the original source:
Sprint Bioscience's NIMA program is focused on the target protein NNMT and will be launched at the BIO International convention - Marketscreener.com

Description

The Center for Genomics and Systems Biology (CGSB) at New York University Abu Dhabi (NYUAD) invites applications from individuals to be appointed as a Postdoctoral Associate. The position will be based at NYU Abu Dhabi and supervised by Dr. Kirsten Sadler Edepli.

The Postdoctoral Associate will use bioinformatics tools applied to genomics datasets and experimental approaches to study regeneration, development, or other biological processes. Projects in the Edepli lab integrate datasets from model organisms (mice and zebrafish) to understand how altering the epigenetic landscape promotes or restricts liver regeneration in mice.

Applicants must have a PhD in biological sciences, genetics, genomics, cell biology, physiology, or related fields. Applicants who have sold expertise in epigenetics, epigenomics, and multi-omics and who seek to join a dynamic and creative team of scientists focused on the epigenetic mechanisms regulating regeneration across diverse species will be considered.

The terms of employment include highly competitive salary, housing allowance, and other benefits. Applications are accepted immediately and candidates will be considered until the position is filled. To be considered, all applicants must submit a cover letter, curriculum vitae, transcript of degree, a one-page summary of research accomplishments and interests, and at least 2 letters of recommendation, all in PDF format. If you have any questions, please email:nyuad.cgsb@nyu.edu

About NYUAD:

NYU Abu Dhabi is a degree-granting research university with a fully integrated liberal arts and science undergraduate program in the Arts, Sciences, Social Sciences, Humanities, and Engineering. NYU Abu Dhabi, NYU New York, and NYU Shanghai, form the backbone of NYUs global network university, an interconnected network of portal campuses and academic centers across six continents that enable seamless international mobility of students and faculty in their pursuit of academic and scholarly activity. This global university represents a transformative shift in higher education, one in which the intellectual and creative endeavors of academia are shaped and examined through an international and multicultural perspective. As a major intellectual hub at the crossroads of the Arab world, NYUAD serves as a center for scholarly thought, advanced research, knowledge creation, and sharing, through its academic, research, and creative activities.

EOE/AA/Minorities/Females/Vet/Disabled/Sexual Orientation/Gender Identity Employer

UAE Nationals are encouraged to apply.

Equal Employment Opportunity Statement

For people in the EU, click here for information on your privacy rights under GDPR:www.nyu.edu/it/gdpr

NYU is an equal opportunity employer committed to equity, diversity, and social inclusion.

Read more here:
Post-Doctoral Associate in the Center for Genomics and Systems Biology job with NEW YORK UNIVERSITY ABU DHABI | 291713 - Times Higher Education